O objetivo deste estudo foi caracterizar a influência da melatonina sobre a atividade de colinoceptores nicotínicos em miotubos de rato em cultura e determinar seu mecanismo de ação. Neste modelo verificamos que a melatonina reduz a densidade de sítios de ligação para ?-bungarotoxina e também a produção de AMP cíclico induzida por forscolina, adenosina e CGRP, mas não por isoprenalina. Estes efeitos foram mimetizados por N-acetilserotonina e 4-P-PDOT, mas não por 2-Iodo-melatonina e 5-MCA-NAT, e foram bloqueados por luzindol. A redução da produção de AMP cíclico não foi inibida por toxina pertussis. O calmidazolium bloqueia tanto a redução da densidade dos colinoceptores nicotínicos quanto a inibição da produção de AMP cíclico. Avaliando a via da guanilil ciclase determinamos que melatonina e calmidazolium inibem a produção de GMP cíclico induzida por KCl. Podemos concluir que a melatonina não está atuando via receptores de membrana, mas provavelmente, está atuando internamente bloqueando a enzima calmodulina. / The objective of this study was characterize the influence of melatonin on the nicotinic-colinoceptors activity in myotube culture from rats and seeks its action mechanism. In this model we demonstrated that melatonin decreases the binding-sites density to ?-bungarotoxin and cyclic AMP synthesis induced by forskolin, adenosine and CGRP, but not by isoprenaline. These effects were mimetized by N-acetylserotonin and 4-P-PDOT, but not by 2-iodomelatonin and 5-MCA-NAT and were blocked by luzindol. Reduction of the cyclic AMP synthesis was not inhibited by pertussis toxin. Calmidazolium blocked both the reduction of nicotinic colinoceptors density and the inhibition of AMP cyclic synthesis. After evaluate the guanylyl cyclase via, we determined that melatonin and calmidazolium inhibit the cyclic GMP synthesis induced by KCl. Then we concluded that melatonin does not act via membrane receptors, but probably, acts blocking the calmodulin enzyme.

Nicotine exerts a therapeutic effect in ulcerative colitis (UC) but the mechanism underlying this effect, is not clear. However, this effect may imply that nicotine has some, as yet to be discovered, effect on the immune system. The aim of the work described in this thesis was to characterise the nicotinic acetylcholine receptors (nAChRs) on human peripheral blood lymphocytes in term of receptor subtype. To achieve this, a combination of radioligand binding assays, pharmacological and molecular biological techniques were used. The data obtained from the binding studies suggested that the presence of one binding site for (-)- nicotine on human peripheral blood lymphocytes with a Kd 15 ± 5.759 nM (1.5 ± 5.759 x 10-8 M) and Bmax 2253 ± 409 sites/cell. The competition studies showed that ligands competing with [3H]-(-)-nicotine were (-)-nicotine, epibatidine and α-bungarotoxin, while others ligands for nAChRs displaced radiolabelled nicotine in insignificant quantities. Thus, radioligand-binding experiments suggest that the binding site for nicotine on human peripheral blood lymphocytes is a nAChR containing α7 and possibly α4 or/and b2 containing nAChR subunits. No evidence was obtained to suggest the presence of a non-cholinergic nicotine receptor. Furthermore, considerable subject to subject variation in the specific binding of radiolabelled nicotine was observed. Because of this only tentative conclusions could be drawn from radioligand binding data. Polymerase chain reaction (RT-PCR) was then used to demonstrate mRNA for the subunits of nAChRs suggested by radioligand binding studies. Data obtained show that the human peripheral blood lymphocytes tested, expressed mRNAs for α4, α5, α7, β2 neuronal nAChRs subunits and β1 muscle nAChR subunit. Expression of the α5 mRNA subunit of nAChR was observed in the lymphocytes in each sample of lymphocytes tested. In contrast, the expression pattern of mRNAs for α4, α7, β1, and β2 mRNAs subunits of nAChRs, varied between individuals. Finally, Western blot analysis was used to confirm that mRNA expression resulted in the expression of protein for nAChR subunits in human peripheral lymphocytes using monoclonal antibodies against α4, α5, α7, and β2 nAChR subunits, which had been detected by RT-PCR. The results obtained from the Western blot analysis show that protein for α4, α5, and α7 nAChR subunits was expressed in most, but not all of the human peripheral blood lymphocyte samples tested and some of the bands obtained were faint. In contrast, protein for the β2 nAChR subunit was observed in a few samples tested and the bands were faint. From the results obtained in this study, it is possible to conclude that human peripheral blood lymphocytes may contain nAChRs with subunit compositions of α4β2, α4β2α5, and/or α7. However, further studies are necessary to show whether or not the single binding site for nicotine demonstrated by radioligand binding experiments is due to one or all of these nAChRs. Thus, the findings of the present study suggest the presence of nAChR on human peripheral blood lymphocytes. Nicotine and its effect may occur through these non- neuronal nAChRs mechanisms. Such a mechanism of action could account for the beneficial of nicotine in ulcerative colitis. Furthermore, a compound that acts on these receptors, but not on nAChRs found on other cells may have therapeutic utility in the treatment of inflammation.